Paper · 22827641
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM and 4 others. Thyroid, 2012. Cited by 41 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Papers, record 22827641. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/22827641
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma | Major topic |
| Iodine Radioisotopes | Major topic |
| Lung Neoplasms | Major topic |
| Thyroid Neoplasms | Major topic |
| Adolescent | |
| Adult | |
| Aged | |
| Child | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Retrospective Studies | |
| Treatment Outcome | |
| Whole-Body Counting | |
| Young Adult |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,708,930 | Predicting radioiodine therapy response in advanced and recurrent thyroid cancer. | Endocr Relat Cancer | 2026 | https://conductscience.org/library/papers/42708930 | PubMed |
| 42,661,840 | Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy. | Cancer Innov | 2026 | https://conductscience.org/library/papers/42661840 | PubMed |
| 41,462,213 | Nomogram for survival prediction in metastatic differentiated thyroid cancer and survival comparison between systemic chemotherapy and local radiotherapy in high-risk patients. | World J Surg Oncol | 2025 | https://conductscience.org/library/papers/41462213 | PubMed |
| 41,142,541 | Predictive factors for re-recurrence in papillary thyroid carcinoma following reoperation: a retrospective analysis. | Gland Surg | 2025 | https://conductscience.org/library/papers/41142541 | PubMed |
| 40,844,370 | 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. | Thyroid | 2025 | https://conductscience.org/library/papers/40844370 | PubMed |
| 40,414,995 | Less is more: once vs. multiple radioactive iodine (RAI) therapy in patients with RAI-avid pulmonary micrometastatic differentiated thyroid cancer. | Eur J Nucl Med Mol Imaging | 2025 | https://conductscience.org/library/papers/40414995 | PubMed |
| 40,318,680 | Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. | Lancet Diabetes Endocrinol | 2025 | https://conductscience.org/library/papers/40318680 | PubMed |
| 39,336,848 | Match Point: Nuclear Medicine Imaging for Recurrent Thyroid Cancer in TENIS Syndrome-Systematic Review and Meta-Analysis. | J Clin Med | 2024 | https://conductscience.org/library/papers/39336848 | PubMed |
| 37,627,224 | Efficacy of Empirical Radioiodine Therapy in Patients with Differentiated Thyroid Cancer and Elevated Serum Thyroglobulin without Evidence of Structural Disease: A Propensity Score Analysis. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37627224 | PubMed |
| 36,324,095 | The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma. | BMC Surg | 2022 | https://conductscience.org/library/papers/36324095 | PubMed |
1 to 10 of 27
See all 27 cited byGenes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/22827641
GET https://conductscience.org/api/papers/v1/22827641/cited_by?page=2